Literature DB >> 25466551

Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.

Marco A Magalhaes1, Sa'ar Minha1, Fang Chen1, Rebecca Torguson1, Al Fazir Omar1, Joshua P Loh1, Ricardo O Escarcega1, Michael J Lipinski1, Nevin C Baker1, Hironori Kitabata1, Hideaki Ota1, William O Suddath1, Lowell F Satler1, Augusto D Pichard1, Ron Waksman2.   

Abstract

BACKGROUND: Clinical presentation of bare metal stent in-stent restenosis (ISR) in patients undergoing target lesion revascularization is well characterized and negatively affects on outcomes, whereas the presentation and outcomes of first- and second-generation drug-eluting stents (DESs) remains under-reported. METHODS AND
RESULTS: The study included 909 patients (1077 ISR lesions) distributed as follows: bare metal stent (n=388), first-generation DES (n=425), and second-generation DES (n=96), categorized into acute coronary syndrome (ACS) or non-ACS presentation mode at the time of first target lesion revascularization. ACS was further classified as myocardial infarction (MI) and unstable angina. For bare metal stent, first-generation DES and second-generation DES, ACS was the clinical presentation in 67.8%, 71.0%, and 66.7% of patients, respectively (P=0.470), whereas MI occurred in 10.6%, 10.1%, and 5.2% of patients, respectively (P=0.273). The correlates for MI as ISR presentation were current smokers (odds ratio, 3.02; 95% confidence interval [CI], 1.78-5.13; P<0.001), and chronic renal failure (odds ratio, 2.73; 95% CI, 1.60-4.70; P<0.001), with a protective trend for the second-generation DES ISR (odds ratio, 0.35; 95% CI, 0.12-1.03; P=0.060). ACS presentations had an independent effect on major adverse cardiac events (death, MI, and re-target lesion revascularization) at 6 months (MI versus non-ACS: adjusted hazard ratio, 4.06; 95% CI, 1.84-8.94; P<0.001; unstable angina versus non-ACS: adjusted hazard ratio, 1.98; 95% CI, 1.01-3.87; P=0.046).
CONCLUSIONS: ISR clinical presentation is similar irrespective of stent type. MI as ISR presentation seems to be associated with patient and not device-related factors. ACS as ISR presentation has an independent effect on major adverse cardiac events, suggesting that ISR remains a hazard and should be minimized.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  drug-eluting stents; restenosis; stents

Mesh:

Substances:

Year:  2014        PMID: 25466551     DOI: 10.1161/CIRCINTERVENTIONS.114.001341

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  18 in total

1.  Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents.

Authors:  Lei Song; Gary S Mintz; Dong Yin; Myong Hwa Yamamoto; Chee Yang Chin; Mitsuaki Matsumura; Khady Fall; Ajay J Kirtane; Manish A Parikh; Jeffrey W Moses; Ziad A Ali; Richard A Shlofmitz; Akiko Maehara
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-09       Impact factor: 2.357

2.  In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents.

Authors:  Takashi Kajiya; Hiroshi Yamaguchi; Junichiro Takaoka; Kengo Fukunaga; Ryoichi Arima; Akihiro Miyamura; Toshiko Ninomiya; Nobuhiko Atsuchi; Yoshihiko Atsuchi; Mitsuyasu Terashima; Hideaki Kaneda; Mitsuru Ohishi
Journal:  Singapore Med J       Date:  2018-04-10       Impact factor: 1.858

3.  In-Stent Restenosis: Pathophysiology and Treatment.

Authors:  Patrick M Looser; Luke K Kim; Dmitriy N Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

Review 4.  Coronary In-Stent Restenosis: Predictors and Treatment.

Authors:  Helen Ullrich; Maximilian Olschewski; Thomas Münzel; Tommaso Gori
Journal:  Dtsch Arztebl Int       Date:  2021-09-24       Impact factor: 8.251

Review 5.  Contemporary Management of Stent Failure: Part One.

Authors:  Nikhil Pal; Jehangir Din; Peter O'Kane
Journal:  Interv Cardiol       Date:  2019-02

6.  In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes.

Authors:  Ganesh Paramasivam; Tom Devasia; Ashwal Jayaram; Abdul Razak U K; M Sudhakar Rao; Rajesh Vijayvergiya; Krishnananda Nayak
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

7.  In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario.

Authors:  Ganesh Paramasivam; Tom Devasia; Shabeer Ubaid; Ashwitha Shetty; Krishnananda Nayak; Umesh Pai; Mugula Sudhakar Rao
Journal:  Egypt Heart J       Date:  2019-11-27

8.  Clinical Impact of High-Sensitivity Cardiac Troponin T on the Chronic Phase of Stable Angina after a Successful Initial Percutaneous Coronary Intervention.

Authors:  Hiroshi Okamoto; Teruyoshi Kume; Terumasa Koyama; Tomoko Tamada; Ryotaro Yamada; Yoji Neishi; Shiro Uemura
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

9.  Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction.

Authors:  Wouter S Remkes; Erik A Badings; Renicus S Hermanides; Saman Rasoul; Jan-Henk E Dambrink; Petra C Koopmans; Salem Hk The; Jan Paul Ottervanger; A T Marcel Gosselink; Jan Ca Hoorntje; Harry Suryapranata; Arnoud Wj van 't Hof
Journal:  Open Heart       Date:  2016-11-17

10.  Identification of Risk Factors Influencing In-Stent Restenosis with Acute Coronary Syndrome Presentation.

Authors:  Jae Young Cho
Journal:  Chonnam Med J       Date:  2017-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.